{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:49:03Z","timestamp":1758386943599,"version":"3.44.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40120-025-00803-0","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:59:05Z","timestamp":1754114345000},"page":"2053-2061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential use of OnabotulinumtoxinA and Erenumab in Chronic Migraine: Retrospective Real-World Report on Bidirectional Switching"],"prefix":"10.1007","volume":"14","author":[{"given":"Carolin Luisa","family":"Hoehne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysenur","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Hendrik","family":"Overeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin Sophie","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira Pauline","family":"Fitzek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"Angerh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9758-1494","authenticated-orcid":false,"given":"Bianca","family":"Raffaelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"803_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383:1866\u201376.","journal-title":"N Engl J Med"},{"key":"803_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"GBD 2021 Nervous System Disorders Collaborators","year":"2024","unstructured":"GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23:344\u201381.","journal-title":"Lancet Neurol"},{"key":"803_CR3","doi-asserted-by":"publisher","first-page":"033310242513215","DOI":"10.1177\/03331024251321500","volume":"45","author":"R Ornello","year":"2025","unstructured":"Ornello R, Caponnetto V, Ahmed F, et al. Evidence-based guidelines for the pharmacological treatment of migraine, summary version. Cephalalgia. 2025;45:03331024251321500.","journal-title":"Cephalalgia"},{"key":"803_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"S Aurora","year":"2010","unstructured":"Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793\u2013803.","journal-title":"Cephalalgia"},{"key":"803_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","volume":"19","author":"L Bendtsen","year":"2018","unstructured":"Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19:91.","journal-title":"J Headache Pain"},{"key":"803_CR6","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/head.13849","volume":"60","author":"R Burstein","year":"2020","unstructured":"Burstein R, Blumenfeld AM, Silberstein SD, et al. Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review. Headache J Head Face Pain. 2020;60:1259\u201372.","journal-title":"Headache J Head Face Pain"},{"key":"803_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/0333102416636843","volume":"36","author":"X Zhang","year":"2016","unstructured":"Zhang X, Strassman AM, Novack V, et al. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors\u2019 responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle? Cephalalgia. 2016;36:875\u201386.","journal-title":"Cephalalgia"},{"key":"803_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J Headache Pain. 2022;23:67.","journal-title":"J Headache Pain"},{"key":"803_CR9","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jpain.2013.03.010","volume":"14","author":"S Eftekhari","year":"2013","unstructured":"Eftekhari S, Warfvinge K, Blixt FW, et al. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013;14:1289\u2013303.","journal-title":"J Pain"},{"key":"803_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/papr.13196","volume":"23","author":"A Jaimes","year":"2023","unstructured":"Jaimes A, G\u00f3mez A, Pajares O, et al. Dual therapy with Erenumab and onabotulinumtoxinA: no synergistic effect in chronic migraine: a retrospective cohort study. Pain Pract. 2023;23:349\u201358.","journal-title":"Pain Pract"},{"key":"803_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/toxins14080529","volume":"14","author":"D Scuteri","year":"2022","unstructured":"Scuteri D, Tonin P, Nicotera P, et al. Pooled analysis of real-world evidence supports anti-CGRP mAbs and onabotulinumtoxinA combined trial in chronic migraine. Toxins. 2022;14:529.","journal-title":"Toxins"},{"key":"803_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"11","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol. 2020;11:417.","journal-title":"Front Neurol"},{"key":"803_CR13","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, et al. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci. 2022;43:1273\u201380.","journal-title":"Neurol Sci"},{"key":"803_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-024-01790-7","volume":"25","author":"JB Hong","year":"2024","unstructured":"Hong JB, Israel-Willner H, Peikert A, et al. Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies \u2013 insights from the German NeuroTransData registry. J Headache Pain. 2024;25:90.","journal-title":"J Headache Pain"},{"key":"803_CR15","first-page":"1","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders. Cephalalgia. 2018;38:1\u2013211.","journal-title":"Cephalalgia"},{"key":"803_CR16","doi-asserted-by":"publisher","first-page":"033310242412697","DOI":"10.1177\/03331024241269735","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener H-C, et al. International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia. 2024;44:03331024241269735.","journal-title":"Cephalalgia"},{"key":"803_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"EV Elm","year":"2007","unstructured":"Elm EV, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138.","journal-title":"BMJ"},{"key":"803_CR18","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1097\/j.pain.0000000000002341","volume":"163","author":"K Schmidt","year":"2022","unstructured":"Schmidt K, Berding T, Kleine-Borgmann J, et al. The beneficial effect of positive treatment expectations on pharmacological migraine prophylaxis. Pain. 2022;163:e319\u201327.","journal-title":"Pain"},{"key":"803_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1\u00a0year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:101.","journal-title":"J Headache Pain"},{"key":"803_CR20","doi-asserted-by":"publisher","first-page":"033310242311605","DOI":"10.1177\/03331024231160519","volume":"43","author":"LF Iannone","year":"2023","unstructured":"Iannone LF, Burgalassi A, Vigani G, et al. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study. Cephalalgia. 2023;43:03331024231160519.","journal-title":"Cephalalgia"},{"key":"803_CR21","doi-asserted-by":"publisher","first-page":"1154420","DOI":"10.3389\/fneur.2023.1154420","volume":"14","author":"LH Overeem","year":"2023","unstructured":"Overeem LH, Lange KS, Fitzek MP, et al. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study. Front Neurol. 2023;14:1154420.","journal-title":"Front Neurol"},{"key":"803_CR22","doi-asserted-by":"publisher","first-page":"033310242412888","DOI":"10.1177\/03331024241288875","volume":"44","author":"P Triller","year":"2024","unstructured":"Triller P, Blessing VN, Overeem LH, et al. Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: a retrospective cohort study. Cephalalgia. 2024;44:03331024241288875.","journal-title":"Cephalalgia"},{"key":"803_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","volume":"22","author":"J Talbot","year":"2021","unstructured":"Talbot J, Stuckey R, Crawford L, et al. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment \u2013 real world outcomes. J Headache Pain. 2021;22:5.","journal-title":"J Headache Pain"},{"key":"803_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s10194-024-01813-3","volume":"25","author":"A Scheffler","year":"2024","unstructured":"Scheffler A, Basten J, Menzel L, et al. Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache\u2014a retrospective real-world analysis. J Headache Pain. 2024;25:109.","journal-title":"J Headache Pain"},{"key":"803_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/03331024211067791","volume":"42","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, et al. Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. Cephalalgia. 2022;42:645\u201353.","journal-title":"Cephalalgia"},{"key":"803_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s10194-024-01753-y","volume":"25","author":"R Oliveira","year":"2024","unstructured":"Oliveira R, Gil-Gouveia R, Puledda F. CGRP-targeted medication in chronic migraine-systematic review. J Headache Pain. 2024;25:51.","journal-title":"J Headache Pain"},{"key":"803_CR27","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, Paemeleire K, Reuter U, et al. Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet. 2025;405:1014\u201326.","journal-title":"Lancet"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00803-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:22:30Z","timestamp":1758367350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00803-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00803-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carolin Luisa Hoehne, Aysenur Sahin, Lucas Hendrik Overeem and Cornelius Angeh\u00f6fer have nothing to declare. Kristin Sophie Lange reports a research grant (International Headache Society) and personal fees (Teva, Organon). Mira Pauline Fitzek reports personal fees from Novartis and Teva. Uwe Reuter has no personal fees to report. Institutional fees from Amgen, Abbvie, Lilly, Lundbeck, Novartis, Pfizer, Medscape, Sand Teva, and research funding from Novartis. Bianca Raffaelli reports research grants from Novartis, Lundbeck, German Migraine and Headache Society (DMKG), German Research Foundation (DFG) and Else Kr\u00f6ner-Fresenius-Stiftung, and personal fees from Abbvie, Lundbeck, Novartis, Organon, Perfood and Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The retrospective data analysis of clinical routine data of headache patients has been approved by the Charit\u00e9 Ethical Committee (EA1\/159\/22). No specific ethical approval or written informed consent for participation was required for this study in accordance with the national legislation and the institutional requirements, and followed Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for cohort studies [].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}